Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2–4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison
Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2–4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison
Nieves Lopez-Munoz, Joris Diels, Nikoletta K. Lendvai, Suzy Van Sanden et al.
Journal
Advances in Therapy
Topics
Multiple Myeloma Research and Treatments
article
Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2–4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison
Nieves Lopez-Munoz, Joris Diels, Nikoletta K. Lendvai, Suzy Van Sanden, Seina Lee, Teresa Hernando, Noffar Bar, Simon J. Harrison, Tadao Ishida, Nitin Patel, Jeremy Er, João Vitor Mendes
article en
Abstract
No abstract available for this paper.
Publication Tag
Advances in TherapyVol. 43(3)
Institutions
Johnson & Johnson (United States) (US), Walter and Eliza Hall Institute of Medical Research (AU), Peter MacCallum Cancer Centre (AU), Yale Cancer Center (US), Hospital Universitario 12 De Octubre (ES), Japanese Red Cross Medical Center (JP)